The remaining shunting is associated with infective endocarditis and systemic embolism. Our case series suggests that this strategy is a promising approach for adult patients with severe PAH associated with VSD. Oxford University Press is a department of the University of Oxford. It furthers the University's objective of excellence in research, scholarship, and education by publishing worldwide.
Sign In or Create an Account. Sign In. Advanced Search.
- Airbreathing Propulsion: An Introduction.
- No customer reviews?
- Key Points?
- Financial Management in Health Services (Understanding Public Health).
Article Navigation. Close mobile search navigation Article Navigation. Volume 2. Article Contents. Patient 1. Patient 2. Patient 3. Supplementary material. Treat-and-repair strategy is a feasible therapeutic choice in adult patients with severe pulmonary arterial hypertension associated with a ventricular septal defect: case series Satoshi Akagi.
- Pulmonary Arterial Hypertension: Individualized Treatment Strategies!
- Jesus and the Victory of God.
- Pulmonary arterial hypertension: current therapeutic strategies?
- Principles of Transistor Circuits. Introduction to the Design of Amplifiers, Receivers and Digital Circuits;
Corresponding author. Oxford Academic. Google Scholar. Shingo Kasahara. Toshihiro Sarashina. Kazufumi Nakamura.
Hiroshi Ito. Cite Citation. Permissions Icon Permissions. Abstract Introduction. Pulmonary arterial hypertension , Ventricular septal defect , Treat-and-repair strategy , Case series. Table 1. Figure 1. Open in new tab Download slide. Table 2. Figure 2. Open in new tab. Table 3.
Novel Therapeutic Strategies for the Treatment of Pulmonary Arterial Hypertension
Figure 3. Search ADS. Pulmonary arterial hypertension in congenital heart disease: translational opportunities to study the reversibility of pulmonary vascular disease. Hemodynamic unloading leads to regression of pulmonary vascular disease in rats. Regression of flow-induced pulmonary arterial vasculopathy after flow correction in piglets.
Assessment of operability of patients with pulmonary arterial hypertension associated with congenital heart disease. Marked hemodynamic improvements by high-dose epoprostenol therapy in patients with idiopathic pulmonary arterial hypertension. Presentation, survival prospects, and predictors of death in eisenmenger syndrome: a combined retrospective and case-control study. Pulmonary hypertensive crises following surgery for congenital heart defects in young children.
Long-term outcome of patients operated for large ventricular septal defects with increased pulmonary vascular resistance. Measurement, interpretation and use of haemodynamic parameters in pulmonary hypertension associated with congenital cardiac disease. Bosentan therapy in patients with eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Ambrisentan for pulmonary arterial hypertension due to congenital heart disease. Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups.
Phosphodiesterase-5 inhibitor in eisenmenger syndrome: a preliminary observational study.
Unidirectional valved patch closure of ventricular septal defects with severe pulmonary arterial hypertension. For commercial re-use, please contact journals. Issue Section:. Download all figures. Supplementary data. Supplementary Data. Comments 0. Add comment Close comment form modal. I agree to the terms and conditions. You must accept the terms and conditions. Add comment Cancel. Submit a comment. Comment title.
You have entered an invalid code. Submit Cancel. Thank you for submitting a comment on this article. Your comment will be reviewed and published at the journal's discretion. Please check for further notifications by email. View Metrics. Email alerts New issue alert. Advance article alerts. Article activity alert. Receive exclusive offers and updates from Oxford Academic. More on this topic Dasatinib-induced pulmonary arterial hypertension complicated with scleroderma: a case report. Intravascular B-cell lymphoma: case report of a rare cause of pulmonary arterial hypertension.
Complex transposition of the great arteries with pulmonary arterial hypertension and giant pulmonary artery aneurysm.
Novel strategies for treatment of pulmonary arterial hypertension. - Abstract - Europe PMC
Related articles in Google Scholar. Related articles in PubMed Effectiveness of cognitive behavior therapy for patients with heart failure and depression: A systematic review protocol. Complete Title: The added value of screening fetal echocardiography after normal cardiac views on a detailed ultrasound. Citing articles via Google Scholar.
- Educational information.
- Ensuring Appropriate Access to Pulmonary Arterial Hypertension Therapy;
- Optics: Learning by Computing, with Examples Using Maple, MathCad, Matlab, Mathematica, and Maple.
Precision Oncology. Women's Health. Media Insights. Post-Conference Perspectives.
Institute for Value-Based Medicine News. Currently Reading. Kristin B. Participating Faculty. Pulmonary arterial hypertension PAH is a progressive, complex disease. PAH is a type of pulmonary hypertension PH and can be further categorized into 7 subdivisions, representing a variety of causal and phenotypic factors. Patients with PH, including PAH, are typically fragile and experience multiple comorbidities; they therefore require individualized treatment plans based on their risk status and etiology.
Based on a review of clinical evidence, a wide variety of treatment options exist for PAH, including general measures eg, physical activity and oral anticoagulants , nonspecific pharmacologic intervention eg, calcium channel blockers , and targeted pharmacologic intervention. Guidelines point to a flexible approach, frequently including upfront or sequential combination therapy, to mitigate disease progression.
Payer-driven drug exclusion policies, including formulary restrictions and noncoverage policies, can detract from the ability of providers to offer treatments consistent with guidelines, as they limit access to the range of treatment options needed for individualized patients. Providers must be able to work with each patient to develop a tailored strategy through open access to treatments, leveraging all available options, to mitigate against exacerbation of comorbidities and optimize care.